EXDENSUR

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary DiseaseChronic Rhinosinusitis With Nasal PolypsGranulomatosis With PolyangiitisHypereosinophilic SyndromeEosinophilic Granulomatosis With Polyangiitis

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

32

Veramyst

GSK

Preclinical

463

Xolair

Roche

Preclinical

254

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

305

Asmanex

Novartis

Preclinical

56

Celexa

AbbVie

Preclinical

17

Spiriva

Boehringer Ingelheim

Preclinical

88

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

89

Atrovent

Boehringer Ingelheim

Preclinical

510

Arcoxia

Novartis

Preclinical

—Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Asthma3 trials

The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study

Recruiting·GSK·Phase 3·NCT06979323·150 enrolled

A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old

Not yet recruiting·GSK·Phase 3·NCT07671001·30 enrolled

The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

Recruiting·GSK·Phase 3·NCT07456033·456 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

Completed·GSK·Phase 3·NCT05281523·264 enrolled

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Completed·GSK·Phase 3·NCT05274750·276 enrolled

Chronic Obstructive Pulmonary Disease2 trials

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Recruiting·GSK·Phase 3·NCT06959095·981 enrolled

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Recruiting·GSK·Phase 3·NCT06961214·960 enrolled

Efficacy and Safety1 trial

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Recruiting·GSK·Phase 3·NCT07177339·1,196 enrolled

Hypereosinophilic syndrome1 trial

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Recruiting·GSK·Phase 3·NCT05334368·123 enrolled

2 more indications

Adult1 trial

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Completed·GSK·Phase 1·NCT05602025·140 enrolled

Eosinophilic Granulomatosis With Polyangiitis1 trial

A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy

Active, not recruiting·GSK·Phase 3·NCT05263934·163 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News